Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib + ezetimibe fixed-dose combination in hypercholesterolemia
NCT06005597Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obicetrapib in hypercholesterolemia (4 arms), sponsored by NewAmsterdam Pharma. Primary endpoint: Low-Density Lipoprotein Cholesterol at 84 days. Started Mar 2024; status: completed.
02
Drugs
obicetrapib
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06005597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005597.